GT Biopharma
GTBP
53 hedge funds and large institutions have $32.1M invested in GT Biopharma in 2021 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 14 increasing their positions, 17 reducing their positions, and 10 closing their positions.
40% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 10
8% more funds holding
Funds holding: 49 → 53 (+4)
0.19% less ownership
Funds ownership: 0.71% → 0.52% (-0.19%)
18% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 17
40% less call options, than puts
Call options by funds: $553K | Put options by funds: $925K
54% less capital invested
Capital invested by funds: $69.7M → $32.1M (-$37.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$2.18M |
| 2 |
Two Sigma Investments
New York
|
+$1.63M |
| 3 |
D.E. Shaw & Co
New York
|
+$1.08M |
| 4 |
State Street
Boston,
Massachusetts
|
+$946K |
| 5 |
Renaissance Technologies
New York
|
+$850K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$4.98M |
| 2 |
BlackRock
New York
|
-$2.59M |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$585K |
| 4 |
IEFM
IQ EQ Fund Management
Dublin 2,
Ireland
|
-$544K |
| 5 |
CCM
Conway Capital Management
Burbank,
California
|
-$318K |
GTBP Hedge Fund Activity: Q3 2021 in Review
53 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in GT Biopharma (GTBP) for Q3 2021, worth a combined $32.1M — down 54% from $69.7M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new GTBP positions and 10 closed out — a net gain of 4 holders — while 14 added to existing stakes and 17 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $2.18M. The largest seller was Citadel Advisors, cutting an estimated $4.98M.
- 53 institutional investors held GT Biopharma (GTBP) as of Q3 2021, up from 49 in Q2 2021.
- Funds reported $32.1M of GT Biopharma stock for Q3 2021, down 54% quarter-over-quarter.
- 14 funds opened new GT Biopharma positions in Q3 2021 and 10 closed out, a net change of +4 holders.
- The largest GT Biopharma buyer in Q3 2021 was Morgan Stanley, an estimated $2.18M added.
- The largest GT Biopharma seller in Q3 2021 was Citadel Advisors, an estimated $4.98M sold.
Based on aggregated 13F filings for Q3 2021.